SNX-111: Phase II/III trial

Neurex Corp. (NXCO), Menlo Park, Calif. Product: SNX-111, N-type neuron-specific calcium blocker Indication: Severe and intractable pain in cancer and AIDS Status: Began a pivotal Phase II/III trial ...